Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory Diseases
10 mai 2024 08h00 HE
|
Eterna Therapeutics
Eterna Therapeutics to Present at ASGCT on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line
Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board
08 mai 2024 09h31 HE
|
Eterna Therapeutics
Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board
Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory Diseases
07 mai 2024 08h00 HE
|
Eterna Therapeutics
Eterna Therapeutics to Present at ASGCT on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line
Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on the Development of a mRNA-Engineered iPSC Line which Mimics Native B2M Expression, via Targeted Insertion of HLA-E at the B2M Locus
07 mai 2024 08h00 HE
|
Eterna Therapeutics
Eterna Therapeutics to present a poster at ASGCT on the Development of a mRNA-Engineered iPSC Line, via Targeted Insertion of HLA-E at the B2M Locus
Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors
20 févr. 2024 08h30 HE
|
Eterna Therapeutics
Eterna Therapeutics (ERNA) Announces the Appointment of Peter Cicala, JD, to its Board of Directors
Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)
03 janv. 2024 16h15 HE
|
Eterna Therapeutics
CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell...
Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer
20 déc. 2023 16h15 HE
|
Eterna Therapeutics
CAMBRIDGE, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell...
Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing
14 déc. 2023 18h56 HE
|
Eterna Therapeutics
CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell...
Eterna Therapeutics Appoints James Bristol, Ph.D., Pharmaceutical Research and Drug Discovery Veteran, to Board of Directors
01 nov. 2023 08h30 HE
|
Eterna Therapeutics
CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell...
Eterna Therapeutics Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Lineage Cell Therapeutics
06 sept. 2023 08h00 HE
|
Eterna Therapeutics
mRNA cell engineering strategically targets genes to create novel and potentially superior product profiles for cell transplant therapy applications Novel engineered iPS cell line to be evaluated by...